HighTower Advisors
BTAI icon

HighTower Advisors’s BioXcel Therapeutics BTAI Stock Holding History

HighTower Advisors’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$54.9K Hold
41,000
– – ﹤0.01% 3698
2025
Q4 		$65.6K Buy
41,000
+6,000
+17% +$12.4K ﹤0.01% 3557
2025
Q3 		$89.6K Buy
35,000
+10,400
+42% +$32.8K ﹤0.01% 3556
2025
Q2 		$44.5K Buy
+24,600
New +$40.7K ﹤0.01% 3558

Other funds holding BTAI

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

HighTower Advisors's BTAI Position: Q1 2026 in Review

HighTower Advisors held its BioXcel Therapeutics (BTAI) position steady in Q1 2026 at 41,000 shares worth $54.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3698.

HighTower Advisors first reported a position in BTAI in Q2 2025 and has held it in 4 quarters since. The position peaked at $89.6K in Q3 2025. 40 funds tracked by Wall St. Rank hold BTAI as of Q1 2026.

  • HighTower Advisors held 41,000 shares of BioXcel Therapeutics worth $54.9K as of Q1 2026.
  • HighTower Advisors left its BioXcel Therapeutics share count unchanged in Q1 2026.
  • BioXcel Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #3698 holding.
  • HighTower Advisors first reported a position in BioXcel Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • HighTower Advisors's BioXcel Therapeutics position peaked at $89.6K in Q3 2025.
  • 40 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.